Clinical trials: Liposarcoma
Neoplasms
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
This trial will evaluate safety and efficacy of Letetresgene autoleucel (GSK3377794) in participants with advanced myxoid/round cell liposarcoma or high-grade myxoid liposarcoma.
- Trial name
- NCT02992743
- Testing
- letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- GlaxoSmithKline
Soft Tissue Sarcoma, Fibrous Histiocytoma
Bevacizumab and Radiation Therapy for Sarcomas
The main purpose of this study is to test the effectiveness of bevacizumab in combination with radiation therapy to see what effects (good or bad) they have on patients with soft tissue sarcoma.
- Conditions
- Soft Tissue Sarcoma, Fibrous Histiocytoma, Liposarcoma, Leiomyosarcoma
- Trial name
- NCT00356031
- Testing
- Bevacizumab, Radiation Therapy, Surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Well-differentiated/Dedifferentiated Liposarcoma
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
The researchers are doing this study to find out whether combining the study drugs palbociclib and INCMGA00012 is an effective and safe treatment for advanced liposarcoma. "Funding Source - FDA OOPD"
- Trial name
- NCT04438824
- Testing
- INCMGA00012, Palbociclib
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00334854
- Testing
- doxorubicin hydrochloride, ifosfamide, adjuvant therapy
- Where
- 28 sites in Austria, Belgium and 7 more
- Volunteers
- 250 people
- Sponsor
- European Paediatric Soft Tissue Sarcoma Study Group
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have…
- Trial name
- NCT00031915
- Testing
- imatinib mesylate
- Where
- 10 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Liposarcoma
Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma
To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the combination is safe and has beneficial effects in patients with liposarcoma.
- Trial name
- NCT02343172
- Testing
- HDM201, LEE011
- Where
- 9 sites in Canada, France and 4 more
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Myxoid Liposarcoma
International Prospective Registry on Local Treatment Approaches in MLS
To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)
- Trial name
- NCT04699292
- Testing
- Surgery, Preoperative RT 36Gy, Preoperative RT 50Gy
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- The Netherlands Cancer Institute
Uveal Melanoma, Melanoma
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
- Conditions
- Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma, Metastatic Melanoma
- Trial name
- NCT05607095
- Testing
- Lifileucel (LN-144/LN-145)
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liposarcomas, Dedifferentiated, Liposarcoma - Well Differentiated
A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
The purpose of this study is to determine whether ribociclib are effective and safe in the treatment of progressive well/dedifferentiated liposarcoma (WDL/DDL).
- Conditions
- Liposarcomas, Dedifferentiated, Liposarcoma - Well Differentiated, Liposarcoma; Mixed Type, Soft-Tissue Sarcoma
- Trial name
- NCT03096912
- Testing
- Ribociclib
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Assaf-Harofeh Medical Center
Sarcoma
Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX
RATIONALE: Collecting and storing samples of tumor tissue from patients with soft tissue sarcoma to test in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00900211
- Testing
- microarray analysis, molecular diagnostic method, biologic sample preservation procedure
- Where
- 12 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- The Christie NHS Foundation Trust
Sarcoma, Soft Tissue
The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma
This is a phase II trial to explore the feasibility of PD-1 immune check point inhibitor, sintilimab, in combination of stand of care chemotherapy in first-line treatment of selected soft tissue sarcoma.
- Trial name
- NCT04356872
- Testing
- Sintilimab, Doxorubicin Hydrochloride, Ifosfamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery
This phase Ib trial studies the side effects and best dose of ribociclib when giving together with doxorubicin hydrochloride in treating patients with soft tissue sarcomas that has spread to other places or that cannot be removed…
- Conditions
- Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma
- Trial name
- NCT03009201
- Testing
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- OHSU Knight Cancer Institute
Solid Tumors, Sarcoma
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
This 2-part study will evaluate safety, tolerability, and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors.
- Trial name
- NCT06644755
- Testing
- DS-2243a
- Where
- 7 sites in United States, Belgium and 3 more
- Volunteers
- 150 people
- Sponsor
- Daiichi Sankyo
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating…
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01154452
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy such as doxorubicin and ifosfamide use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00061984
- Testing
- pegfilgrastim, doxorubicin hydrochloride, ifosfamide
- Where
- 41 sites in Austria, Belgium and 9 more
- Volunteers
- 455 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
This phase II trial studies how well cixutumumab and temsirolimus work in treating patients with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways.
- Conditions
- Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma
- Trial name
- NCT01614795
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 76 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Liposarcoma, Dedifferentiated
Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma
This study is open to adults with a type of cancer called dedifferentiated liposarcoma (DDLPS). They can join the study if their tumours are positive for MDM2.
- Trial name
- NCT06058793
- Testing
- Brigimadlin
- Where
- 56 sites in United States, Argentina and 5 more
- Volunteers
- 138 people
- Sponsor
- Boehringer Ingelheim
Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
This phase I trial studies the side effects and best way to give NY-ESO-1 specific T cells after cyclophosphamide in treating patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.
- Conditions
- Adult Synovial Sarcoma, Myxoid/Round Cell Liposarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
- Trial name
- NCT02059850
- Testing
- Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cyclophosphamide, Laboratory Biomarker Analysis
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Liposarcoma, Dedifferentiated
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
Study SPH4336-US-01 is an open-label (no placebo), multicenter clinical trial to evaluate the safety, blood levels (pharmacokinetics) and preliminary anti-tumor effects of SPH4336, a selective enzyme blocker, in patients with…
- Trial name
- NCT05580588
- Testing
- SPH4336
- Where
- 9 sites in United States
- Volunteers
- 14 people
- Sponsor
- Shanghai Pharma Biotherapeutics USA Inc.
Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma
Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma
This phase III trial compares chest computed tomography (CT) to chest x-ray (CXR) for lung surveillance after curative-intent resection of high-risk truncal-extremity soft tissue sarcoma.
- Conditions
- Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma, AJCC Grade 3 Sarcoma, Alveolar Soft Part Sarcoma
- Trial name
- NCT06526897
- Testing
- Biopsy, Chest Computed Tomography, Chest Radiography
- Volunteers
- 1,582 people
- Sponsor
- ECOG-ACRIN Cancer Research Group